Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY: XBI )

79.86 +0.76 (+0.96%)
Streaming Delayed Price Updated: 11:45 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SPDR Series Trust SPDR S&P Biotech ETF

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
“Knockin’ On Heaven’s Door” Stock Market (And Sentiment Results)
We’ve come through the “point of control” on the S&P 500. This simply means there is less “overhead supply” to come on the market as we press higher. 
Via Talk Markets
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
Thermo Fisher, Principal Financial Group, And Two Promising ETFs Steal The Show On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named SPDR S&P Biotech ETF (NYSE: XBI), which is trading in a tight range < 
Via Benzinga
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
Time to Spring-Clean...Your Stock Portfolio
Plus, Howard Marks, co-founder of Oaktree Capital Management, joins the podcast to discuss topics including China's effect on inflation in the U.S. 
Via The Motley Fool
April Is Busting Out For Healthcare And Biotech
Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend. 
Via Talk Markets
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
Via Benzinga
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
The Stock Market Rally May Fizzle The Week Of April 3
I think what we’ve seen over the last week or two has been driven by systematic trading and rebalancing of portfolios, as investors have sold financials and moved into mega-cap technology names. But... 
Via Talk Markets
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
“Don’t Stop Believin'” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, bullish percent ticked up to 22.5% from 20.9% the previous week. 
Via Talk Markets
This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips
T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment. 
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
Can Healthcare Stocks Survive Macro Headwinds?
Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year. 
Via Talk Markets
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Biotech Stocks And The SVB Collapse — Here's What We Know
The collapse of SVB will have a big impact on early-stage, venture-backed companies. 
Via Investor's Business Daily
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ: 
Via Benzinga
Small Cap Biotechs Slammed By SVB Collapse
Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation. 
Via Talk Markets
6 Stock Market Thoughts For The Week Of March 13
A flight to safety seemed to be at play this week, with the market seeking safety first and asking questions later. This is not unusual, and once the situation is resolved, much of the decline in rates... 
Via Talk Markets
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the  SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth, 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.